- 現金殖利率: N/A、總殖利率: 0、5年平均現金配發率: N/A
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024 (10) | -1.32 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
2023 (9) | 0.07 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
2022 (8) | -2.70 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
2021 (7) | -3.02 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
2020 (6) | -3.82 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
2019 (5) | -3.48 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
---|---|---|---|---|---|---|---|---|---|
24Q4 (20) | 0.28 | 140.0 | 134.57 | 0.11 | 115.07 | 115.49 | -1.32 | 18.01 | -1985.71 |
24Q3 (19) | -0.70 | -55.56 | -134.48 | -0.73 | -30.36 | -141.71 | -1.61 | -78.89 | -280.9 |
24Q2 (18) | -0.45 | 0.0 | 26.23 | -0.56 | 0.0 | -1.82 | -0.90 | -100.0 | 23.73 |
24Q1 (17) | -0.45 | 44.44 | 21.05 | -0.56 | 21.13 | -9.8 | -0.45 | -742.86 | 21.05 |
23Q4 (16) | -0.81 | -139.9 | -76.09 | -0.71 | -140.57 | -91.89 | 0.07 | -92.13 | 102.59 |
23Q3 (15) | 2.03 | 432.79 | 422.22 | 1.75 | 418.18 | 436.54 | 0.89 | 175.42 | 139.38 |
23Q2 (14) | -0.61 | -7.02 | 62.58 | -0.55 | -7.84 | 56.35 | -1.18 | -107.02 | 27.61 |
23Q1 (13) | -0.57 | -23.91 | 0 | -0.51 | -37.84 | 0 | -0.57 | 78.89 | 0 |
22Q4 (12) | -0.46 | 26.98 | 74.16 | -0.37 | 28.85 | 69.42 | -2.70 | -19.47 | 10.6 |
22Q3 (11) | -0.63 | 61.35 | 0 | -0.52 | 58.73 | 0 | -2.26 | -38.65 | 0 |
22Q2 (10) | -1.63 | 0 | -24.43 | -1.26 | 0 | -51.81 | -1.63 | 0 | -24.43 |
年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
---|---|---|---|---|---|---|---|---|---|---|
2025/2 | 0.0 | 0.0 | 0.0 | 0.0 | -100.0 | 0.04 | N/A | 本年累計營收較去年減少,係因去年認列銷貨收入。 | ||
2025/1 | 0.0 | -100.0 | -100.0 | 0.0 | -100.0 | 0.04 | N/A | 本月營收較去年同期減少,係因去年本月認列銷貨收入。 | ||
2024/12 | 0.04 | 0.0 | 0.0 | 1.68 | -46.71 | 1.17 | 0.21 | 本月營收較去年同期增加,係因本月認列銷貨收入;本年累計較去年同期減少,係因前期認列授權簽約金收入。 | ||
2024/11 | 0.0 | -100.0 | 0.0 | 1.63 | -48.12 | 1.54 | 0.16 | 本年累計較去年同期減少,係因前期認列授權簽約金收入較高所致。 | ||
2024/10 | 1.13 | 175.35 | 0.0 | 1.63 | -48.12 | 1.54 | 0.16 | 本月營收較去年同期增加,係因本月認列授權簽約金收入;本年累計較去年同期減少,係因前期認列授權簽約金收入較高所致。 | ||
2024/9 | 0.41 | 0.0 | 0.0 | 0.51 | -83.93 | 0.41 | 0.46 | 本月營收較去年同期增加,係因本月認列銷貨收入;本年累計較去年同期減少,係因前期認列授權簽約金收入。 | ||
2024/8 | 0.0 | 0.0 | 0.0 | 0.1 | -96.94 | 0.0 | 0 | 去年係因認列授權簽約金收入。 | ||
2024/7 | 0.0 | 0.0 | -100.0 | 0.1 | -96.94 | 0.1 | 1.99 | 去年同期係因認列授權簽約金收入。 | ||
2024/6 | 0.0 | -100.0 | 0.0 | 0.1 | 0.0 | 0.1 | 3.77 | 銷售L606研發用藥及保健食品 | ||
2024/5 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 3.77 | 銷售L606研發用藥 | ||
2024/4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | N/A | 銷售保健食品之營收 | ||
2024/3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | N/A | 銷售保健食品之營收 | ||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A |